NRXBF (NurExone Biologic) Net Issuance of Debt : $-0.03 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. NurExone Biologic's net issuance of debt for the three months ended in Dec. 2024 was $-0.01 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.03 Mil.

NurExone Biologic Net Issuance of Debt Historical Data

The historical data trend for NurExone Biologic's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Net Issuance of Debt Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Issuance of Debt

1.12

0.10

-0.03

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Issuance of Debt	Get a 7-Day Free Trial										-0.01	-0.01	-0.01	-0.01	-0.01

NurExone Biologic Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

NurExone Biologic Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.